Key Change for Retinal (Retinaldehyde, CAS 116-31-4)
Latest Australian regulations (as of mid-2026) focus mainly on AICIS (for chemical introduction/ingredients in cosmetics) rather than a new TGA ban specific to retinol or retinal concentrations in finished skincare products.
Key Change for Retinal (Retinaldehyde, CAS 116-31-4)
From 27 June 2026, retinal can no longer be imported or manufactured in Australia under the AICIS exempted or reported introduction categories if it has any consumer end use, including as a cosmetic/skincare ingredient (serums, creams, moisturisers, etc.).
Introducers (importers and manufacturers) must apply for and receive an AICIS assessment certificate before introducing retinal for consumer use.
This follows a targeted human health hazard assessment that classified retinal as having developmental toxicity (presumed human developmental toxicant / Reproduction Category 1 under GHS, based on its relation to retinoic acid and data from related retinoids).
Existing stock already in Australia can continue to be sold and used (including in local manufacture). New imports/manufacture of the ingredient or formulated products containing it require the certificate.
Overseas direct-to-consumer sellers to Australian customers are generally unaffected by the AICIS introduction rules.
Application involves fees (industry sources noted a minimum around $24,100 for a health-focused assessment, plus any data needs; a “comparable hazard assessment” option with reduced fee is available because AICIS has already assessed the hazard). Assessment timeframe is typically 70 working days once started (excluding stoppages for more information). AICIS accepts relevant retinol reproductive toxicity data for these applications.
This does not apply to retinol (CAS 68-26-8) or retinol esters that are listed on the Australian Inventory of Industrial Chemicals. Those remain eligible under previous introduction pathways.
Broader TGA / Cosmetic vs Therapeutic Framework
TGA regulates products as therapeutic goods (requiring ARTG listing) if they make therapeutic claims (e.g., treating acne, repairing sun damage, preventing disease) or contain scheduled ingredients used therapeutically. Purely cosmetic claims (improving appearance, moisturising, anti-ageing appearance benefits) keep products as cosmetics.
AICIS regulates the industrial chemical ingredients in cosmetics that are not therapeutic goods.
Poisons Standard (SUSMP): Vitamin A is in Schedule 4 (prescription) except for topical preparations containing 1% or less of Vitamin A (and certain internal-use limits). This exemption supports cosmetic-strength topical use of vitamin A derivatives.
Other retinoid derivatives have specific scheduling history (e.g., hydroxypinacolone retinoate unscheduled up to 0.5% for dermal use; ethyl lactyl retinoate received an exemption for ≤0.1% dermal cosmetic use effective around early 2026). Prescription retinoids such as tretinoin remain Schedule 4.
There is no general concentration ban or new tight limit on retinol itself in Australian cosmetics comparable to the EU’s rules (EU limits retinol/retinyl acetate/retinyl palmitate to 0.3% retinol equivalents in most leave-on products and 0.05% in body lotions, with labelling, phased in from late 2025). Australia has not adopted equivalent concentration caps for retinol/retinal at the time of the latest available information. Industry and clinic guidance often references practical cosmetic ranges (e.g., retinol ≤1%, retinaldehyde ≤0.1%), but these are not hard regulatory maximums under the current Poisons Standard exemption.
Practical Implications for Skincare Products
Retinol and ester products continue under existing rules (provided they stay cosmetic in claims and formulation and comply with any Inventory listing conditions).
Retinal products face a higher barrier for new introduction/import due to the mandatory assessment certificate.
Claims matter: Avoid therapeutic language that could reclassify a product under TGA.
Labelling and consumer safety (pregnancy warnings are commonly advised for retinoids due to known developmental risks of the vitamin A class) remain important under general consumer law (ACCC) and cosmetic information standards.
AICIS is the primary body for the recent retinal change; check the official AICIS site for application guidance and the published evaluation statement (EVA00186, June 2026).
For the most current official details, refer directly to:
AICIS announcement and evaluation statements on industrialchemicals.gov.au
TGA guidance on cosmetics vs therapeutic goods
Current Poisons Standard
Regulations can evolve (further scheduling reviews of vitamin A derivatives have been recommended in related evaluations), so verify with the regulators or a compliance specialist for commercial decisions.
